Tafenoquine and ACTs (TADORE- Plus)

Starting soon · Phase 4

Conditions studied: Vivax Malaria

In brief

A trial designed to determine whether there is a clinically significant drug-drug interaction of tafenoquine with DHA-piperaquine or artesunate-pyronaridine using a control arm with radical cure given at the end of follow up (delayed radical cure).

Key facts

Study ID

NCT07060794

Run by

Menzies School of Health Research

People needed

507

Starts

2026-06-01

Expected to finish

2028-06-01

Last updated by the study team

2026-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• P. vivax peripheral parasitaemia (mono-infection)
• G6PD normal status (G6PD activity ≥70% of the adjusted male median
• as determined by the Standard G6PD (SD Biosensor, ROK))
• Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours
• Age ≥18 years
• Haemoglobin at presentation ≥8g/dl
• Written informed consent.
• Living in the study area and willing to be followed for six months

You may not qualify if…

• Danger signs or symptoms of severe malaria
• Pregnant or lactating females
• Regular use of drugs with haemolytic potential
• Known hypersensitivity to any of the study drugs
• History of any psychiatric disorder

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.